$31 million to progress pipeline of genetic modifiers in cancer and rare diseases

March 10, 2022
Business Services

Scenic Biotech has announced a Series A financing of roughly $31 million, supporting the creation of new programmes based on …

MHRA approves Phase I/II clinical trial of IN3BIO vaccine for colorectal cancer patients

March 10, 2022
Business Services

The MHRA has approved a Phase I/II clinical trial of IN3BIO’s colorectal cancer vaccine. This is the company’s second global …

Vicore adds to rare lung disease pipeline with PAH indication

March 9, 2022
Research and Development

Vicore Pharma has announced plans to initiate a clinical trial with C21 in pulmonary arterial hypertension (PAH).

NICE draft guidance does not recommend pembrolizumab plus chemo for triple negative breast cancer

March 9, 2022
Research and Development

Draft guidance published by NICE for public consultation does not recommend pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) for …

Omicron sub-variant BA.2 makes up 11.6% of COVID-19 variants in US

March 9, 2022
Research and Development

The CDC said that the BA.2 sub-variant of Omicron is estimated to be 11.6% of the coronavirus variants circulating in …

MHRA authorisation of new treatment for chronic kidney disease associated with diabetes

March 9, 2022
Research and Development

The MHRA has authorised the use of Kerendia® (finerenone) (10mg or 20mg), an oral, first-in-class non-steroidal, selective mineralocorticoid receptor (MR) …

Moderna announces its global public health strategy

March 8, 2022

Moderna has announced its global public health strategy through four new initiatives which aim to advance mRNA vaccines for the …

Study may see end of need for invasive endometriosis diagnosis surgery

March 8, 2022
Manufacturing and Production

A new study of women living with endometriosis is underway, exploring the potential of Artificial intelligence (AI), and cutting-edge medical …

Neuraxpharm expands in Southeast Europe

March 8, 2022
Manufacturing and Production

Neuraxpharm Group have announced the expansion of its business in Southeast Europe, through the acquisition of Brain Therapeutics, a company …

Major US study finds COVID-19 vaccines not linked to deaths

March 8, 2022
Manufacturing and Production

A study into vaccine side-effects, based in the US, has found no link between two COVID-19 jabs and the number …

Malaysia to receive Pfizer’s COVID-19 pills in two weeks, says Health Minister

March 7, 2022
Sales and Marketing

Khairy Jamaluddin, Health Minister of Malaysia, has shared that the country expects to receive its first shipment of Pfizer’s oral …

HUTCHMED receives $15 million to begin Phase III study of lung cancer treatment

March 7, 2022
Sales and Marketing

HUTCHMED has received $15 million from AstraZeneca, for the initiation of start-up activities for SAFFRON, the first global Phase III …

AbbVie acquires Syndesi Therapeutics

March 7, 2022
Sales and Marketing

Syndesi Therapeutics has been acquired by AbbVie in a deal worth a potential $1 billion.Syndesi was created in 2018 as …

India: approval for drug treating CKD-associated anaemia

March 7, 2022
Sales and Marketing

Zydus Lifesciences received approval from the Drugs Controller General of India (DCGI) for its new drug application for Oxemia (Desidustat). …

Phase III trial into nirsevimab for RSV treatment yields positive results

March 4, 2022
Medical Communications

The latest results from Sanofi and AstraZeneca’s Phase III trial nirsevimab support the vaccine’s ability to protect all infants from …

Median Technologies iBiopsy Lung Cancer Screening Software

March 4, 2022
Medical Communications

Median Technologies has announced that the company has filed a regulatory submission to the FDA for its iBiopsy Lung Cancer …

Promising treatment targeting 40% mortality Candida infection

March 4, 2022
Medical Communications

A Promising Innovation Medicine (PIM) designation has been awarded to rezafungin by the MHRA, for the treatment of invasive candidiasis. …

Anti-inflammatory baricitinib is a life-saving COVID-19 drug

March 4, 2022
Medical Communications

UK experts say they have identified another life-saving drug that can alleviate COVID-19 illness. The anti-inflammatory baricitinib is usually used …

Risk of hospitalisation five times higher with J&J

March 3, 2022
Business Services, Medical Communications

A study published in Jama Network Open has revealed that Johnson & Johnson’s coronavirus vaccine was far less effective at …

FDA grants breakthrough therapy designation to RSV vaccine

March 3, 2022
Business Services, Medical Communications

The FDA has granted a Breakthrough Therapy Designation to Pfizer’s respiratory syncytial virus (RSV) vaccine candidate, for the prevention of …

The Gateway to Local Adoption Series

Latest content